Related Experiment Video
Updated: May 25, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma
1Central South University, Department of Orthopedics, The Second Xiangya Hospital, Hunan, China.
Abstract:
Autophagy is a catabolic process critical to maintaining cellular homeostasis and responding to cytotoxic insult. Autophagy is recognized as "programmed cell survival" in contrast to apoptosis or programmed cell death. Upregulation of autophagy has been observed in many types of cancers and has been demonstrated to both promote and inhibit antitumor drug resistance depending to a large extent on the nature and duration of the treatment-induced metabolic stress as well as the tumor type. Cisplatin, doxorubicin and methotrexate are commonly used anticancer drugs in osteosarcoma, the most common form of childhood and adolescent cancer. Our recent study demonstrated that high mobility group box 1 protein (HMGB1)-mediated autophagy is a significant contributor to drug resistance in osteosarcoma cells. Inhibition of both HMGB1 and autophagy increase the drug sensitivity of osteosarcoma cells in vivo and in vitro. Furthermore, we demonstrated that the ULK1-FIP200 complex is required for the interaction between HMGB1 and BECN1, which then promotes BECN1-PtdIns3KC3 complex formation during autophagy. Thus, these findings provide a novel mechanism of osteosarcoma resistance to therapy facilitated by HMGB1-mediated autophagy and provide a new target for the control of drug-resistant osteosarcoma patients.
Insights
High mobility group box 1 protein (HMGB1)-mediated autophagy promotes drug resistance in osteosarcoma. Inhibiting HMGB1 and autophagy enhances cancer therapy effectiveness, offering new treatment targets.
Area of Science:
- Oncology
- Cell Biology
- Molecular Medicine
Background:
- Autophagy, a cellular process for homeostasis and stress response, is implicated in cancer drug resistance.
- Osteosarcoma, a prevalent childhood cancer, often exhibits resistance to standard treatments like cisplatin, doxorubicin, and methotrexate.
- High mobility group box 1 protein (HMGB1) has been linked to cellular processes influencing cancer progression and treatment outcomes.
Purpose of the Study:
- To investigate the role of HMGB1-mediated autophagy in osteosarcoma drug resistance.
- To elucidate the molecular mechanism by which HMGB1 influences autophagy and drug sensitivity.
- To identify potential therapeutic targets for overcoming drug resistance in osteosarcoma.
Main Methods:
- Cellular and molecular biology techniques were employed to study autophagy and drug resistance.
- Experiments involved manipulating HMGB1 and autophagy pathways in osteosarcoma cells.
- The interaction between HMGB1, ULK1-FIP200 complex, and BECN1-PtdIns3KC3 complex was analyzed.
Main Results:
- HMGB1-mediated autophagy significantly contributes to drug resistance in osteosarcoma cells.
- Inhibition of both HMGB1 and autophagy markedly increased osteosarcoma cell sensitivity to anticancer drugs in vitro and in vivo.
- The ULK1-FIP200 complex mediates the interaction between HMGB1 and BECN1, promoting autophagy.
Conclusions:
- HMGB1-mediated autophagy represents a novel mechanism driving therapeutic resistance in osteosarcoma.
- Targeting HMGB1 and autophagy simultaneously offers a promising strategy to enhance drug efficacy in osteosarcoma.
- These findings provide a new therapeutic avenue for managing drug-resistant osteosarcoma.
